EUVIMEDEUVIMED entdecken
Crossref

P-353: From metabolic imbalance to clinical control: a new strategy in Prader-Willi syndrome

S de Loredo, A Correa Barovero, L Garraza, L Vallejo, K Fuentes

Hormone Research in Paediatrics · 04.11.2026 · 99 (Supplement_4)

DOI: 10.1159/hrp/adaag020.411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 04.11.2026. Verfasst von S de Loredo und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Prader-Willi syndrome is a genetic disorder characterized by hypotonia and early-onset hyperphagia, with a high risk of metabolic complications, including type 2 diabetes. Weight loss management in these patients represents a clinical challenge, as lifestyle-based interventions are often insufficient. In this context, new therapeutic strategies have emerged, including GLP-1 receptor agonists, which have demonstrated benefits in metabolic control, weight reduction, and appetite suppression.

Objectives

Describe a novel therapeutic approach that improved metabolic parameters and clinical outcomes in Prader Willi Syndrome Methods Descriptive case report.

Results

We present the case of a 12-year-old female patient with a history of Prader-Willi syndrome associated with severe obesity (weight 75 kg, height 1.38 m, BMI 39.4 kg/m2) and type 2 diabetes. Initial laboratory evaluation at the start of follow-up showed an HbA1c of 8.5% and a fasting blood glucose level of 115 mg/dL (HbA1c in 2024: 6.6%). Treatment was initiated with a GLP-1 receptor agonist (semaglutide 0.5 mg once weekly) in combination with metformin 750 mg/day, and continuous glucose monitoring using a sensor was requested. Five months after treatment initiation, a 2 kg weight loss was observed, accompanied by reduced appetite. Laboratory results showed an HbA1c of 6.8%, consistent with the continuous glucose monitoring data from the 30 days prior to the visit: TIR 87%, TAR (181–250 mg/dL): 4%, TAR (>250 mg/dL): 2%, TBR (54–69 mg/dL): 5%, and TBR (<54 mg/dL): 2%, with an estimated HbA1c of 6.2%.

Conclusions

This case demonstrates the potential benefit of GLP-1 receptor agonists in a pediatric patient with Prader-Willi syndrome, severe obesity, and type 2 diabetes, showing favorable clinical, metabolic, and weight-related outcomes. Therefore, this therapy could be considered a therapeutic option for this population as part of a comprehensive, multidisciplinary approach.

Zitieren

APA

Loredo, S. D., Barovero, A. C., Garraza, L., Vallejo, L., & Fuentes, K. (2026). P-353: From metabolic imbalance to clinical control: a new strategy in Prader-Willi syndrome. Hormone Research in Paediatrics, 99(Supplement_4). https://doi.org/10.1159/hrp/adaag020.411

Vancouver

Loredo SD, Barovero AC, Garraza L, Vallejo L, Fuentes K. P-353: From metabolic imbalance to clinical control: a new strategy in Prader-Willi syndrome. Hormone Research in Paediatrics. 2026;99(Supplement_4). doi:10.1159/hrp/adaag020.411

BibTeX
@article{Loredo2026,
  author = {Loredo, S de and Barovero, A Correa and Garraza, L and Vallejo, L and Fuentes, K},
  title = {P-353: From metabolic imbalance to clinical control: a new strategy in Prader-Willi syndrome},
  journal = {Hormone Research in Paediatrics},
  year = {2026},
  volume = {99},
  number = {Supplement_4},
  doi = {10.1159/hrp/adaag020.411}
}
Kostenlos starten →